Patients undergoing CT colonography, also known as virtual colonoscopy, now take four tablets of the cleansing agent bisacodyl. Mayo instituted the new protocol this summer.
“Our hope is that this will make people less anxious and more likely to get screened and will ultimately result in fewer deaths from colorectal cancer,” said C. Daniel Johnson, MD, chair of the department of radiology at Mayo Clinic in Arizona, in the release.
The protocol was based on a study co-authored by Dr. Johnson that was published in Abdominal Imaging last year. The study found the four-tablet procedure was as effective as the standard liquid laxative for virtual colonoscopies.
The new protocol is not intended for standard colonoscopies.
Related Articles on Gastroenterology:
Study: Narrow Band Imaging Accuracy With Colonoscopy Allows Distal Non-Cancerous Polyps to Remain
Gastroenterologist on the Move: Dr. Kabir Julka Joins IL’s Dreyer Medical Clinic
Crospon Received FDA Clearance for EndoFLIP Gastroenterology Application
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
